Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 22855730)

1.
2.

Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion.

De León DD, Li C, Delson MI, Matschinsky FM, Stanley CA, Stoffers DA.

J Biol Chem. 2008 Sep 19;283(38):25786-93. doi: 10.1074/jbc.M804372200. Epub 2008 Jul 17.

3.

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.

Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Göke B.

Gut. 2006 Feb;55(2):243-51. Epub 2005 Jun 28.

4.
5.

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.

Parkes DG, Pittner R, Jodka C, Smith P, Young A.

Metabolism. 2001 May;50(5):583-9.

PMID:
11319721
6.

Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.

Salehi M, Gastaldelli A, D'Alessio DA.

Gastroenterology. 2014 Mar;146(3):669-680.e2. doi: 10.1053/j.gastro.2013.11.044. Epub 2013 Dec 4.

7.

Evidence that glucagon stimulates insulin secretion through its own receptor in rats.

Kawai K, Yokota C, Ohashi S, Watanabe Y, Yamashita K.

Diabetologia. 1995 Mar;38(3):274-6.

PMID:
7758872
8.

Glucagon-like peptide-1 is a physiological incretin in rat.

Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR.

J Clin Invest. 1995 Jan;95(1):417-21.

9.

Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.

Gu W, Winters KA, Motani AS, Komorowski R, Zhang Y, Liu Q, Wu X, Rulifson IC, Sivits G Jr, Graham M, Yan H, Wang P, Moore S, Meng T, Lindberg RA, Véniant MM.

Am J Physiol Endocrinol Metab. 2010 Oct;299(4):E624-32. doi: 10.1152/ajpendo.00102.2010. Epub 2010 Jul 20.

10.
11.

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR.

Diabetes. 1999 Jan;48(1):86-93.

PMID:
9892226
12.

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.

D'Alessio DA, Vogel R, Prigeon R, Laschansky E, Koerker D, Eng J, Ensinck JW.

J Clin Invest. 1996 Jan 1;97(1):133-8.

13.

Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility.

Miki T, Minami K, Shinozaki H, Matsumura K, Saraya A, Ikeda H, Yamada Y, Holst JJ, Seino S.

Diabetes. 2005 Apr;54(4):1056-63.

14.
15.

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M.

J Clin Invest. 1998 Apr 1;101(7):1421-30.

16.
17.

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.

Diabetes. 1996 Nov;45(11):1524-30.

PMID:
8866556
18.
19.

Glucagon-like peptide-1 and islet lipolysis.

Sörhede Winzell M, Ahrén B.

Horm Metab Res. 2004 Nov-Dec;36(11-12):795-803.

PMID:
15655711
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk